PPARGC1A and sarcopenia: On this basis, we argue that further studies testing this hypothesis will provide a basis for more broadly understanding the therapeutic potential of PGC-1α as a countermeasure for sarcopenia [95], as well as further illuminating the mechanisms of NMJ deterioration in aging muscle.